海正生材 20250624 摘要 2024 年聚乳酸市场受供需关系影响，价格明显下降，产能利用率仅 30%-40%。国内外新产能投放预计将进一步压低价格，但因已接近成 本价，降幅或有限。 全球聚乳酸市场由 NatureWorks 和道达尔科比恩主导，国内海正生材 占有重要地位。海正生材国内市场占有率约为 43%，并通过扩产计划进 一步提升产能。 环保政策对聚乳酸需求影响显著，但实际推行力度不及预期。3D 打印领 域则呈现独立增长，尤其消费级 FDM 3D 打印受益于技术迭代，用户体 验提升。 公司消费级 FDM 3D 打印业务自 2023 年起显著增长，受益于拓竹科技 的技术创新。巨鹿山地区 FDM 增材消耗量占比高，预计 2024 年达 70%。 中美贸易战对公司 3D 打印材料出货量无实质影响，主要市场在欧美， 占比约 80%-85%，国内市场成长空间大。 全球 3D 打印材料需求快速增长，预计 2026 年可能达到 10 万吨。欧美 地区在工业制造、医疗器械等领域的应用推动了需求增长。 公司认为聚乳酸树脂（PLA）在 FDM 桌面打印中具有较大发展前景，其 气味少、体验感好，且占据行业先机，具有成长性和 ...

Group 1 - The company, Henan Jindan Lactic Acid Technology Co., Ltd., has issued 7,000,000 convertible bonds with a total fundraising amount of RMB 700 million, net proceeds amounting to RMB 689.61 million [1][2] - The bonds, named "Jindan Convertible Bonds" with code "123204," began trading on the Shenzhen Stock Exchange on August 2, 2023 [2] - The company has decided to postpone the completion date of its fundraising project related to the annual production of 75,000 tons of polylactic acid biodegradable materials from August 2025 to June 2026 due to various factors including project complexity and market conditions [4][6] Group 2 - The total investment for the fundraising project is RMB 1.03 billion, with RMB 700 million planned to be raised from the current bond issuance [4] - As of May 31, 2025, the cumulative investment in the project is RMB 689.61 million, with RMB 612.31 million already invested [4][5] - The company is a leading player in the domestic lactic acid industry, focusing on the production, sales, and research of lactic acid and its derivatives for 40 years, and is expanding its biodegradable materials circular industry chain [5][6]

均瑶健康上演"地天板" 今天， "常温乳酸菌第一股"均瑶健康上演"地天板"，走出6天5板，成交额超8亿元 。 今天，A股迎来6月开门红，三大指数集体上涨，全市场超3300只个股飘红。 板块方面，中韩自贸区、新消费、足球概念、贵金属、医药相关板块涨幅靠前。 个股方面， 新消费概念股均瑶健康（605388）上演"地天板"，走出6天5板 ；若羽臣涨停，万辰集团涨 超14%，双双创历史新高；创新药龙头股舒泰神"20CM"涨停；广晟有色涨停，股价创阶段新高。 截至收盘，上证指数涨0.43%，深证成指涨0.16%，创业板指涨0.48%。市场成交额为1.16万亿元。 国金证券研报称，上周医药板块表现强势，其中创新药板块尤其值得关注。国家药监局批准11款全新创 新药的上市申请，另外还有2款创新药拟纳入优先审评，为相关企业业绩增长提供助力。同时政策端对 创新药的支持持续，叠加海外授权交易不断落地，创新药景气度有望持续。建议重点关注仿创药板块重 估机会。此外，一季报后景气度反转和业绩改善，也将带来连锁药房、器械、CXO、仿制药、中药、 医疗服务等板块投资机会。 5月30日，均瑶健康发布股价异动公告称，公司不存在应披露而未披露事项 ...

以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 截至 2025年3月31日，全国专精特新小巨人企业超1.4万家。 其中江苏以 2160家领先全国，广东 1985家位居第二位，浙江1804家、山东1162家、北京1036家分别位列第三至第五位。 一级市场趋冷，小巨人融资事件及金额均下降五成左右。 2025Q1，专精特新小巨人企业一级市场发 生融资事件136起，同比下降55.0%，已披露融资金额98.5亿元，同比下降48.1%。 IPO减缓，但A股新增IPO中小巨人占比提升。 2025Q1，19家专精特新小巨人企业IPO，同比增长 26.7%； A股新增27家IPO企业中，专精特新小巨人企业18家，占比66.7%，较2024Q4（74.2%） 下降7.5个百分点。 并购活跃，小巨人企业成为并购热门标的。 2025Q1披露以专精特新小巨人企业为标的的并购事件 29起，同比增长262.5%；已披露交易金额共51.6亿元，同比增长26.8%。 小巨人企业发展概况 专精特新小巨人企业总量超 1.4万 ...

(责任编辑：王治强HF013) 【4月30日，国内"常温乳酸菌第一股"均瑶健康公布2025年一季报】均瑶健康2025年第一季度营收4.01 亿元，同比增长1.41%，净利润1090.71万元，同比下降58.29%。公司益生菌业务增速可观，第二曲线加 速成型，2025年一季度益生菌食品板块收入同比上涨139.19%，电商渠道收入同比增长1173.33%。年报 显示，2024年公司营业收入14.58亿元，其中益生菌饮品及食品收入7.92亿元。当下益生菌市场发展迅 速，预计到2025年全球益生菌产业产值将超770亿美元，中国市场占比超25%。均瑶健康加大自主研 发，构建产业链一体化闭环体系，子公司均瑶润盈是相关标准制定参与者，自主知识产权的益生菌菌种 资源库扩增，产品丰富。在上游端，均瑶润盈掌握原材料，推进募投项目建设。产品层面，培育核心产 品矩阵，下游环节建立一体化生态链模型，实现渠道布局。报告期内，公司新拓展电商渠道，联合推动 低温益生菌饮品上市，注重优化仓配成本。公司海外业务增速亮眼，2024年主营业务在国际市场营收约 8460万元，同比增长24.54%，2025年一季度海外市场收入同比大涨77.43%。均瑶 ...

Core Viewpoint - The Chinese government is promoting a "Weight Management Year" initiative, which is expected to significantly boost the health industry, potentially exceeding a trillion yuan in market size. This creates a favorable environment for companies like Junyao Health, which is focusing on expanding its leadership in the probiotic market and enhancing its product offerings [1][2]. Group 1: Company Performance - Junyao Health reported revenues of approximately 1.458 billion yuan for 2024 and 401 million yuan for the first quarter of 2025, with a notable 139.19% increase in probiotic food revenue in Q1 2025 [1][3][4]. - The company achieved a gross margin of 38.39% in 2024, an increase of 1.98% from the previous year, attributed to reduced raw material costs and optimized operational management [3][4]. Group 2: Market Trends - The health industry in China is projected to reach a market size of 13.4 trillion yuan by 2025 and further grow to 29.1 trillion yuan by 2030, driven by the "Healthy China 2030" strategy [2]. - The probiotic market in China has seen significant growth, with a compound annual growth rate of 14% from 2018 to 2022, increasing from 64.77 billion yuan to approximately 109.38 billion yuan [5]. Group 3: Product Development - Junyao Health is expanding its product line to include low-temperature active probiotic beverages, leveraging innovative fermentation technology and developing functional beverages that combine probiotics with other beneficial ingredients [2][4]. - The company has developed a diverse range of health functional beverages, including products targeting beauty, eye health, sleep, and nutrition, to meet various consumer health needs [2][4]. Group 4: Strategic Initiatives - Junyao Health is enhancing its research and development capabilities by integrating with leading companies in the probiotic sector, establishing a comprehensive "R&D-production-sales" integrated system to strengthen its market position [6][7]. - The company is expanding its e-commerce presence, with a significant increase in online sales, particularly in the first quarter of 2025, where e-commerce revenue surged by 1,173.33% [4][8]. Group 5: International Expansion - Junyao Health's international business achieved revenue of approximately 84.6 million yuan in 2024, a year-on-year increase of 24.54%, with Q1 2025 showing a remarkable growth of 77.43% [9]. - The company exports to over 80 countries and regions, positioning itself as a leading exporter of probiotics in China, benefiting from competitive pricing and stable supply chains [9]. Group 6: Future Outlook - With the release of production capacity, strengthened technological barriers, and expanded brand influence, Junyao Health is expected to continue leading the health industry and achieve long-term stable growth [10].